January 24th 2024
Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.
Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs
October 15th 2021In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.
Formulation and Functional Considerations for Delivering Biologics in Prefilled Syringes
January 8th 2018Graham Reynolds, vice-president and general manager, Global Biologics at West Pharmaceutical Services, Inc., shares insights on key considerations when developing a biologic drug product in a prefilled syringe.
Lilly to Invest $72 Million for Insulin Manufacturing Upgrade
October 23rd 2017The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.